This technology is a method of removing disease-associated amyloid fibril deposits using targeted antibodies to enhance the patient’s cellular immune response.
The pathological accumulation of amyloid proteins is implicated in a variety of chronic inflammatory disorders, cancers, and neurodegenerative diseases. However, current approaches for treatment and removal of amyloid deposits, such as high-dose chemotherapy, steroids, and stem cell replacement, are highly invasive but rarely achieve complete remission.
This treatment uses amyloid-directed antibodies to enhance the patient’s own cellular immune clearance mechanism to facilitate removal of disease-associated fibril deposits. The binding of the antibody to the amyloid fibrils, which normally avoid detection by the immune system, triggers a response from the patient’s immune system, facilitating destruction and removal of the deposit.
This technology has been validated in vivo in a mouse model of amyloidosis and is being investigated in human patients.
Patent Issued (US 8,105,594)
IR Proxy61
Licensing Contact: Jerry Kokoshka
